JP2009535298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535298A5 JP2009535298A5 JP2009502932A JP2009502932A JP2009535298A5 JP 2009535298 A5 JP2009535298 A5 JP 2009535298A5 JP 2009502932 A JP2009502932 A JP 2009502932A JP 2009502932 A JP2009502932 A JP 2009502932A JP 2009535298 A5 JP2009535298 A5 JP 2009535298A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer
- anticancer agent
- cancer cells
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/389,695 US9107863B2 (en) | 2006-03-27 | 2006-03-27 | Reagents and methods for cancer treatment and prevention |
| US11/389,695 | 2006-03-27 | ||
| PCT/US2007/007526 WO2007126787A2 (en) | 2006-03-27 | 2007-03-27 | Reagents and methods for cancer treatment and prevention |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170115A Division JP5712257B2 (ja) | 2006-03-27 | 2013-08-20 | 癌の処置および予防のための試薬および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009535298A JP2009535298A (ja) | 2009-10-01 |
| JP2009535298A5 true JP2009535298A5 (enExample) | 2011-05-12 |
| JP5422377B2 JP5422377B2 (ja) | 2014-02-19 |
Family
ID=38533710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502932A Expired - Fee Related JP5422377B2 (ja) | 2006-03-27 | 2007-03-27 | 癌の処置および予防のための試薬および方法 |
| JP2013170115A Expired - Fee Related JP5712257B2 (ja) | 2006-03-27 | 2013-08-20 | 癌の処置および予防のための試薬および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170115A Expired - Fee Related JP5712257B2 (ja) | 2006-03-27 | 2013-08-20 | 癌の処置および予防のための試薬および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9107863B2 (enExample) |
| EP (2) | EP2974738B1 (enExample) |
| JP (2) | JP5422377B2 (enExample) |
| CN (1) | CN101443036A (enExample) |
| AU (1) | AU2007245169B2 (enExample) |
| CA (1) | CA2647542A1 (enExample) |
| ES (2) | ES2548435T3 (enExample) |
| WO (1) | WO2007126787A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376495B2 (ja) | 1992-08-18 | 2003-02-10 | ソニー株式会社 | 接着剤の塗布方法及び接着治具 |
| US9107863B2 (en) * | 2006-03-27 | 2015-08-18 | The Buck Institute For Age Reasearch | Reagents and methods for cancer treatment and prevention |
| CZ300806B6 (cs) * | 2007-07-18 | 2009-08-12 | Ústav experimentální mediciny AV CR, v.v.i. | Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy |
| BR112015023088A2 (pt) * | 2013-03-15 | 2017-11-21 | Genspera Inc | método para preparar um composto, e, composto |
| EP2796137A1 (en) * | 2013-04-22 | 2014-10-29 | Universität des Saarlandes | SERCA inhibitor and Calmodulin antagonist combination |
| CN112891354B (zh) * | 2021-03-18 | 2022-10-21 | 新乡医学院 | MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US20010033839A1 (en) * | 1999-10-04 | 2001-10-25 | Emilio Barbera-Guillem | Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| JP2001010973A (ja) * | 1999-06-29 | 2001-01-16 | Dnavec Research Inc | がんワクチン |
| PL354997A1 (en) * | 1999-09-25 | 2004-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US7056491B2 (en) * | 2000-11-08 | 2006-06-06 | Wisconsin Alumni Research Foundation | Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators |
| CA2356438A1 (en) * | 2001-09-05 | 2003-03-05 | Andre Pichette | Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers |
| EP2128267A2 (en) * | 2001-10-31 | 2009-12-02 | Astellas Pharma Inc. | Methods of evaluating phosphatase inhibitors |
| US20030235818A1 (en) * | 2002-04-08 | 2003-12-25 | Vsevolod Katritch | Immunogenic peptides, and method of identifying same |
| AU2003301526A1 (en) | 2002-10-25 | 2004-05-13 | University Of Connecticut Health Center | Immunotherapy of cancer through controlled cell lysis |
| ES2469670T3 (es) * | 2003-11-30 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores |
| US9107863B2 (en) * | 2006-03-27 | 2015-08-18 | The Buck Institute For Age Reasearch | Reagents and methods for cancer treatment and prevention |
-
2006
- 2006-03-27 US US11/389,695 patent/US9107863B2/en not_active Expired - Fee Related
-
2007
- 2007-03-27 ES ES07754097.9T patent/ES2548435T3/es active Active
- 2007-03-27 AU AU2007245169A patent/AU2007245169B2/en not_active Ceased
- 2007-03-27 CA CA002647542A patent/CA2647542A1/en not_active Abandoned
- 2007-03-27 CN CNA2007800162837A patent/CN101443036A/zh active Pending
- 2007-03-27 WO PCT/US2007/007526 patent/WO2007126787A2/en not_active Ceased
- 2007-03-27 EP EP15180408.5A patent/EP2974738B1/en not_active Not-in-force
- 2007-03-27 JP JP2009502932A patent/JP5422377B2/ja not_active Expired - Fee Related
- 2007-03-27 ES ES15180408.5T patent/ES2655909T3/es active Active
- 2007-03-27 EP EP07754097.9A patent/EP2004219B1/en not_active Not-in-force
-
2010
- 2010-04-29 US US12/770,638 patent/US8895031B2/en active Active
-
2013
- 2013-08-20 JP JP2013170115A patent/JP5712257B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-15 US US14/800,412 patent/US9885704B2/en active Active
-
2017
- 2017-12-22 US US15/852,606 patent/US20180128816A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3010497B1 (en) | A combination of tetrahydrocannabinol and cannabidiol for use for increasing radiosensitivity in the treatment of a brain tumour | |
| Sultan et al. | Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial | |
| JP2021525154A (ja) | 細胞膜透過性を増加させるための交流電界の使用 | |
| SG161307A1 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
| SI1551409T1 (sl) | Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka | |
| JP2009535298A5 (enExample) | ||
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| Łasińska et al. | Basal cell carcinoma: pathology, current clinical treatment, and potential use of lipid nanoparticles | |
| Farooqi | Regulation of deregulated cell signaling pathways by pomegranate in different cancers: Re-interpretation of knowledge gaps | |
| IL174525A0 (en) | Medicamentously targeted local lipolysis | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| DE60311788D1 (de) | Kombinationstherapie zur behandlung von krebs | |
| ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
| Ficai et al. | Nanostructures for cancer therapy | |
| DK1653964T3 (da) | Cancerkombinationsterapi omfattende AZD2171 og ZD1839 | |
| DK1965801T3 (da) | Kombination af azd2171 og pemetrexed | |
| YU63702A (sh) | Novo antitelo sa specifičnošću za rak debelog creva | |
| IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
| NO20064755L (no) | Kombinasjonsterapi | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| NO20056171L (no) | Kombinasjonsterapi | |
| Moar et al. | Evolution of targeted therapies in cancer: opportunities and challenges | |
| de Oliveira Santana et al. | Study Current and Future Therapies in the Treatment of Cancer | |
| Thompson et al. | Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5:: JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia | |
| Liu et al. | Advances on lung cancer metastasis |